Latha Vairavan - 06 May 2025 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role
SVP Chief Financial Officer
Signature
/s/ Masaru Matsuda, Attorney-in-Fact for Latha Vairavan
Issuer symbol
ARQT
Transactions as of
06 May 2025
Net transactions value
$0
Form type
4
Filing time
07 May 2025, 19:29:54 UTC
Next filing
05 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Vairavan Latha SVP Chief Financial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE /s/ Masaru Matsuda, Attorney-in-Fact for Latha Vairavan 07 May 2025 0002065881

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Award $0 +20,000 +44% $0.000000 65,104 06 May 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARQT Stock Option (right to buy) Award $0 +60,000 $0.000000 60,000 06 May 2025 Common Stock 60,000 $14.32 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") that will vest as to 25% of the RSUs on each annual anniversary of May 1, 2025 (the "Vesting Commencement Date"), beginning on May 1, 2026, subject to the Reporting Person's continued service through the vesting date.
F2 The options will vest and become exercisable as to 1/48th of the shares on each monthly anniversary of May 6, 2025 (the "Vesting Commencement Date"), subject to the Reporting Person's continued service through the applicable vesting date.